Skip to main content
Haitao Pan, PhD
Haitao Pan, PhD

Haitao Pan, PhD

Assistant Member, St. Jude Faculty



PhD - Graduate School of Biomedical Sciences, The University of Texas Health Science Center MD Anderson Cancer Center, Houston Texas
PhD - Fourth Military Medical University, Xi’an Shaanxi, China
MS - Xi’an University of Electronic Science and Technology (Xidian) , Xi’an Shaanxi, China

Research Interests

  • Bayesian Adaptive Clinical Trials Design
  • Nonparametric Bayesian Modelling
  • Statistical Computation
  • Longitudinal Data Analysis

Selected Publications

Mu R, Xu G, Liu G, Pan H*. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials. Contemporary Clinical Trials Jul 22;108:106504, 2021. *Corresponding author

Wu J, Pan H*, Hsu C-W. Bayesian single‐arm phase II trial designs with time‐to‐event endpoints. Pharmaceutical Statistics 2021. PMID: 34085764 *Corresponding author  

Li C, Pan H*. A phase I dose-finding design with incorporation of historical information and adaptive shrinking boundaries. PLoS One. Aug 27;15(8):e0237254, 2020. doi: 10.1371/journal.pone.0237254. eCollection 2020.

Mu R, Pan H, Xu G. A Bayesian adaptive phase I/II platform trial design for pediatric immunotherapy trials. Stat Med Oct 22, 2020. doi: 10.1002/sim.8780. Corresponding author

Khan RB, Bano M, Wang F, Pan H, Christensen A, Smith J, Simmons A, Sadighi ZS. Height, weight, and cardiovascular effects of stimulants on children with brain tumors. Pediatr Blood Cancer Oct 13;e28740, 2020. doi: 10.1002/pbc.28740

Oshiro Y, Mizumoto M, Pan H, Kaste SC, Gajjar A, Merchant TE.. Spinal changes after craniospinal irradiation in pediatric patients. Pediatr Blood Cancer Dec;67(12):e28728, 2020. doi: 10.1002/pbc.28728

Qin N, Li Z, Song N, Wilson CL, Easton J, Mulder H, Plyler E, Neale G, Walker E, Zhou X, Pan H, Hudson MM, Yasui Y, Robison LL, Zhang J, Ness KK, Wang Z.  Epigenetic Age Acceleration and Chronic Health Conditions among Adult Survivors of Childhood Cancer. J Natl Cancer Inst Sep 24;djaa147, 2020. doi: 10.1093/jnci/djaa147

Mizumoto M, Oshiro Y, Pan H, Wang F, Kaste SC, Gajjar A, Chemaitilly W, Merchant TE. Height after photon craniospinal irradiation in pediatric patients treated for central nervous system embryonal tumors. Pediatr Blood Cancer 2020 Jul 26;e28617, 2020. doi: 10.1002/pbc.28617

Wallace D, Taylor DR, Pan H, Hwang S,Lucas JT Jr, Klimo Jr P, Upadhyaya SA, Boop FA. Treatment-related calvarial lesions in pediatric brain tumor survivors. Pediatr Blood Cancer Jun;67(6):e28189, 2020. doi: 10.1002/pbc.28189. 

Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharm Stat Apr 5, 2020. doi: 10.1002/pst.2013. [Epub ahead of print]

Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials Mar 7;92:105972, 2020. doi: 10.1016/j.cct.2020.105972. [Epub ahead of print]

Xu H, Pan H, Wang Y,  Zhang J. Expanded study on the risk of lymphovascular space invasion and lymph node metastasis of endocervical adenocarcinoma using Pattern Classification: a single-centre analysis of 213 cases. Pathology 51(6):570-78, 2019. (Co-First author)

Wu K, Pan H, Li C, Zhao Q, Wang L, Xia J. An evaluation roadmap for critical quality attributes from tier 1 in analytical similarity assessment. PLoS One Dec 6;13(12):e0208354, 2018. doi: 10.1371/journal.pone.0208354. eCollection 2018. (Co-First Author)

Lavado A, Park JY, Paré J, Finkelstein D, Pan H, Xu B, Fan Y, Kumar RP, Neale G, Kwak YD, McKinnon PJ, Johnson RL, Cao X. The Hippo Pathway Prevents YAP/TAZ-Driven Hypertranscription and Controls Neural Progenitor Number. Developmental Cell Dec 3;47:1-16, 2018. doi: 10.1016/j.devcel.2018.09.021

Kejian W, Qingbo Z, Chanjun L, Ling W, Chen L, Pan H*, Jielai X*. Some Statistical Considerations in Analytical similarity Assessment of Biosimilar Studies. Chinese Journal of Health Statistics 35(3):344-348, 2018. (*Corresponding author) (in Chinese)

Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Statistics in Medicine March 2018. DOI: 10.1002/sim.7674 PMID: 29682777

Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Medical Research Methodology March;18:32, 2018.

Pan H, Yuan Y. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials. Stat Med Jan 30;36(2):266-279, 2017. doi: 10.1002/sim.6941. Epub 2016 Mar 16. PubMed PMID: 26991076; PubMed Central PMCID: PMC5026535.

Zhao L, Pan H. Radiotherapy alone or concurrent chemoradaition for esophageal squamous cell carcinoma in elderly patients. Journal of Cancer Research and Clinical Oncology 2017.

Zhao L, Xu M, Jiang W, Pan H, Zang J, Luo S, Wang J, Zhou Y, Shi M. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. Oncotarget Jan 24;8(4):6763-6774, 2017.

Pan H, Yuan Y, Xia J. A calibrated power prior approach to borrow information from historical data with application to biosimilar clinical trials. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2016.

Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials. Statistics in Medicine 35(20):3497-508, 2016.

Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Statistics in Medicine 34(10):1681-94, 2015.

Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C, Wang L, Xia J. The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLoS ONE 9(5), 2014.

Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. Spinal Changes of a Newly Isolated Neuropeptide Endomorphin-2 Concomitant with Vincristine-Induced Allodynia. PLoS ONE 9(2):e89583, 2014.

Yang Y, Zhang YG, Lin GA, Xie HQ, Pan HT, Huang BQ, Liu JD, Liu H, Zhang N, Li L, Chen JH. The effects of different hyperbaric oxygen manipulations in rats after traumatic brain injury. Neuroscience Letters 563:38-43, 2014.

Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials 11(1):49-59, 2014.

Pan H, Huang P, Wang Z, Wang L, Li C, Xia J. A Novel Bayesian Seamless Phase I/II Design. PLoS ONE 8(9), 2013.

Pan H, Ji Y, Chen Z, Li C, Xia J. The Choice Of Phase I Bayesian Adaptive Designs In China. International Journal of Drug Discovery 5(1):185-90, 2013.

Pan H, Li C, Wang L, Jiang Z, Xia J. A Three-Stage Bayesian Adaptive Phase I/II Design and Simulation Studies. Communications in Statistics - Simulation and Computation 43(2):254-68, 2013.

Last update: August 2021